SEONGNAM, South Korea – April 7, 2025 – In a landmark agreement poised to reshape the future of neurological drug development, ABL Bio Inc. and global biopharmaceutical giant GSK have announced a worldwide licensing partnership centered on ABL Bio’s proprietary Grabody-B platform. This innovative brain delivery technology is designed to overcome one of neuroscience’s most enduring challenges: crossing the blood-brain barrier (BBB) to deliver therapies effectively to the brain.
The collaboration will support the development of multiple novel therapeutics targeting a broad range of neurodegenerative diseases, including Alzheimer’s and Parkinson’s, by enabling efficient transport of therapeutic agents—such as antibodies, oligonucleotides, and siRNAs—into the brain.
A Strategic Response to an Aging Global Population
The rise in neurodegenerative conditions globally, driven by increasing life expectancy, has intensified the demand for innovative treatments. However, drug development for brain diseases has long been hindered by the BBB, a natural defense mechanism that limits the entry of substances into the brain, including many potentially life-saving medicines.
ABL Bio’s Grabody-B technology targets the Insulin-like Growth Factor 1 Receptor (IGF1R) to actively shuttle therapeutic compounds across the BBB. By enabling molecular transport to previously inaccessible regions of the brain, the platform promises to revolutionize how treatments for neurological disorders are developed and delivered.
Deal Highlights: Multi-Billion Potential
Under the terms of the agreement, ABL Bio will receive up to £77.1 million in upfront and near-term milestone payments, including an immediate £38.5 million payment. The deal also outlines potential research, development, regulatory, and commercialization milestone payments amounting to £2.075 billion across several therapeutic programs. Tiered royalties on net sales will be paid to ABL Bio if the therapies reach commercialization.
GSK will assume responsibility for preclinical and clinical development, manufacturing, and global commercialization. ABL Bio will transfer its Grabody-B technology and related expertise, marking a major step forward in the global reach of its platform.
A Shared Vision for Innovation
Christopher Austin, GSK’s SVP of Research Technologies, emphasized the transformative potential of the collaboration. “There is a critical need for new therapeutics to treat neurodegenerative brain diseases, which are rapidly increasing in prevalence due to the aging of the population,” said Austin. “This agreement reflects our commitment to innovative platform technologies to overcome the BBB and open entirely new opportunities for treating these devastating diseases.”
ABL Bio CEO Sang Hoon Lee highlighted the strategic importance of the partnership. “This agreement underscores ABL Bio’s leadership in BBB technology and its commitment to advancing transformative therapeutics through strategic partnership with global pharmaceutical leaders like GSK,” he stated. “It will also strengthen our position in the neurodegenerative disease treatment market and support expansion into new therapeutic modalities.”
About ABL Bio
ABL Bio is a clinical-stage biotechnology company focused on bispecific antibody therapeutics. Its Grabody platform supports a pipeline of clinical and preclinical programs across immuno-oncology and neuroscience. ABL Bio’s diverse portfolio includes assets such as ABL001 (tovecimig), which has been granted Fast Track designation by the U.S. FDA, and ABL111 (givastomig), a triple-combination therapy currently undergoing Phase 1b clinical evaluation. The company is also advancing bispecific ADCs and novel therapeutic candidates globally.
Cosmael ThinkLab Commentary:
This alliance between ABL Bio and GSK exemplifies the power of platform innovation and cross-border collaboration in biotech. As the industry pushes the boundaries of what is possible in brain-targeted therapeutics, partnerships like this will be instrumental in transforming scientific potential into clinical reality.